Related Experiment Video
Updated: Jul 14, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine
Lars H Jensen1, Kathleen D Danenberg, Peter V Danenberg
1Department of Oncology, Danish Colorectal Cancer Group South, University of Southern Denmark, Vejle Hospital, Denmark. lars.henrik.jensen@vgs.regionsyddanmark.dk
Purpose:
The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine.
Patients And Methods:
Microdissection of paraffin-embedded tumor tissue, RNA extraction, and quantitative polymerase chain reaction were performed on tumors obtained from 37 patients with advanced CRC.
Results:
The median relative gene expression of MSH2 was 0.65 (quartiles 0.5-0.8) in nonresponders and 1.25 (quartiles 0.92-1.38) for responders (P = 0.038). High expression of MSH2 was associated with a hazard ratio of 0.5 (95% confidence interval, 0.23-1.11; P = 0.083) in survival analysis.
Conclusion:
The higher gene expression of MSH2 in responders and the trend for predicting overall survival indicates a predictive value of this marker in the treatment of advanced CRC with capecitabine.